America's Best Nonprofits
  1. Home
  2. Medical Research
  3. Duarte, CA
  4. Beckman Research Institute

Beckman Research Institute

Beckman Research Institute is ranked among medical research organizations in Duarte, CA, with an America's Best Score of 64 out of 100, based on its 2025 Form 990.

  • Duarte, CA
  • Tax-exempt since 2005
  • EIN: 95-3432210
cityofhope.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
64OF 100 Ranked in Duarte Medical Research How this score is calculated

Organization summary

Beckman Research Institute is a 501(c)(3) organization, classified under Medical Research (NTEE H30). Contributions are tax-deductible.

1500 Duarte Rd, Duarte, CA 91010-3012

In fiscal year 2025 it reported $332,532,052 in revenue and $385,146,731 in expenses, with contributions making up 55.8% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

The specific and primary purpose of the Beckman Research Institute of the city of hope (Beckman Research Institute) is to directly engage in the active conduct of medical research. Please see schedule o for a continuation of our mission.

Main program · fiscal year 2025

  • Biomedical research and disease investigations, including dna synthesis and cell analysis. Beckman Research Institute has pioneered scientific breakthroughs resulting in treatments that have improved the lives of patients worldwide. Numerous life-saving drugs use patented technology developed at Beckman Research Institute. These drugs include synthetic human insulin (humulin) for diabetes, the wid… Read more

    Biomedical research and disease investigations, including dna synthesis and cell analysis. Beckman Research Institute has pioneered scientific breakthroughs resulting in treatments that have improved the lives of patients worldwide. Numerous life-saving drugs use patented technology developed at Beckman Research Institute. These drugs include synthetic human insulin (humulin) for diabetes, the widely used cancer drugs herceptin, rituxan and avastin, and humira for arthritis. Researchers at Beckman Research Institute undertake fundamental investigations in diabetes progression and treatment, immunology and imaging, interfering rnas and HIV treatment, total synthesis of complex and therapeutic natural products, mechanisms of drug action, neurogenesis, STEM cell therapy, dna repair and radiation, and the immunobiology of viral infection. They have achieved major advances in recombinant dna technology, monoclonal antibodies, gene therapy, epigenetics, si-rna technology and cancer immunotherapeutics. A department in Beckman Research Institute is dedicated to understanding and developing treatments based on cancer's interaction with the immune system. Other research has identified proteins that may play critical roles in immune response and may lead to new treatment strategies. Another major emphasis for the Beckman Research Institute scientists is personalized research and medicine -- analyzing a patient's unique genetic profile to develop tailored therapies for their specific disease. All of this research is uniquely supported by onsite manufacturing facilities that can test and produce quantities of cell-based, gene-based and molecular therapies. These facilities further serve as resources for medical and scientific research centers nationwide. Beckman Research Institute scientists serve as faculty members in city of hope's irell & manella graduate school of biological sciences. The graduate school's mission is to train students to be outstanding research scientists in chemical, molecular and cellular biology. The school is accredited by the western association of schools and colleges. Graduates of the program, awarded a doctorate of philosophy in biological sciences, are equipped to address fundamental questions in life sciences and biomedicine for careers in academia, industry and government.

    $318,236,055 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 83¢ went to programs, 17¢ to management and 0¢ to fundraising.

  • Programs $318,236,055
  • Management $66,774,602
  • Fundraising $136,074

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score64 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves37.8 mo; 4.3 mo in cash25 / 25
Financial balance (median margin)−23.5%0 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+1.6% / yr8.3 / 15
Track record21 years8.4 / 10
Debt load46.8% of assets2.6 / 10
Total64.3 → 64
Spending on programs
Not scored; America's Best needs 65%+
83%Meets

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$332,532,052Fiscal year 20252022: $288,276,01320222023: $229,086,53420232024: $285,315,31720242025: $332,532,0522025
Expenses$385,146,731Fiscal year 20252022: $367,599,61320222023: $353,496,34320232024: $382,452,55620242025: $385,146,7312025
Total assets$2,280,669,212Fiscal year 20252022: $1,755,270,54920222023: $1,946,470,77420232024: $2,184,814,08320242025: $2,280,669,2122025
Total liabilities$1,067,230,062Fiscal year 20252022: $626,893,91420222023: $828,494,91220232024: $984,918,50920242025: $1,067,230,0622025
Fiscal year ending September 2025
Revenue$332,532,052
Expenses$385,146,731
Net income−$52,614,679
Net assets$1,213,439,150

Notable sources of revenue

Percent of total revenue
Contributions$185,551,567
Program services$9,102,724
Investment income$114,943,106
Other (net)$22,934,655

Assets / debt

Total assets$2,280,669,212
Total liabilities$1,067,230,062
Net assets$1,213,439,150

Compensation

Not in our extract for this year.

Fiscal year ending September 2024
Revenue$285,315,317
Expenses$382,452,556
Net income−$97,137,239
Net assets$1,199,895,574

Notable sources of revenue

Percent of total revenue
Contributions$165,812,985
Program services$19,939,417
Investment income$83,859,993
Other (net)$15,702,922

Assets / debt

Total assets$2,184,814,083
Total liabilities$984,918,509
Net assets$1,199,895,574

Compensation

Not in our extract for this year.

Fiscal year ending September 2023
Revenue$229,086,534
Expenses$353,496,343
Net income−$124,409,809
Net assets$1,117,975,862

Notable sources of revenue

Percent of total revenue
Contributions$150,737,172
Program services$15,969,208
Investment income$48,687,565
Other (net)$13,692,589

Assets / debt

Total assets$1,946,470,774
Total liabilities$828,494,912
Net assets$1,117,975,862

Compensation

Not in our extract for this year.

Fiscal year ending September 2022
Revenue$288,276,013
Expenses$367,599,613
Net income−$79,323,600
Net assets$1,128,376,635

Notable sources of revenue

Percent of total revenue
Contributions$154,152,878
Program services$25,203,801
Investment income$14,429,552
Other (net)$94,489,782

Assets / debt

Total assets$1,755,270,549
Total liabilities$626,893,914
Net assets$1,128,376,635

Compensation

Officers and key employees$7,033,214
Share of expenses1.9%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?